Advanced Platelet-Rich Fibrin (PRF)
One System, Two Regenerative Solutions
Alocuro’s advanced platelet-concentrating system provides procedure flexibility for clinicians as Platelet-Rich Plasma (PRP) & Platelet-Rich Fibrin (PRF) protocols are possible using the same closed, ARTG-listed device design. This delivers clinical flexibility and eliminates the need for additional equipment.
Whether the clinical indication requires high-dose platelet therapy with PRP, or fibrin-based regeneration support with Pure PRF+, the Alocuro system allows clinicians to tailor treatments to each patient, with confidence that maximum regeneration potential has been delivered to the target site.
Alocuro Pure PRF+
High platelet dose, superior purity, advanced PRF
Alocuro’s ARTG-listed platelet-concentrating system enables preparation of both PRP and PRF from a single platform, giving clinics flexibility to select the most appropriate autologous product without additional specialised equipment.
Unlike many tube‑based PRF systems, Pure PRF+ yields a yellow fibrin scaffold that is RBC‑depleted, and platelet‑rich.
Although Pure PRF+ has a lower platelet dose per millilitre than Alocuro PRP (as higher‑dose PRP requires anticoagulant to maximise platelet separation), Pure PRF+ closely mimics the body’s intrinsic fibrin‑formation process, forming a stable viscous matrix within approximately 45 minutes after centrifugation.
Pure PRF+ is particularly useful in clinical contexts where a fibrin‑based scaffold or an effect of a ‘fibrin glue’ will assist the patient’s clinical situation.
Autologous Fibrin Matrix for Regenerative Procedures
Alocuro Pure PRF+ is an autologous injectate collected from the patient’s own blood, with the Platelet-Rich Fibrin (PRF) delivering regenerative properties similar to Platelet-Rich Plasma (PRP).
However, PRF is different to PRP as it is produced without anticoagulant, allowing the clotting cascade to proceed outside of the body, compared to PRP where this process occurs inside the body after injection.
Alocuro Pure PRF+ protocol creates a patient’s own, physiologic fibrin matrix for injection or surgical placement, with very minimal RBC contamination – hence the ‘pure’ designation.
How is Pure PRF+ Processed?
During centrifugation, platelets and their released growth factors and regenerative proteins are precisely positioned within the plasma, above the packed red blood cells.
The plasma fraction also contains fibrin and leukocytes, providing a rich biological milieu for use at the target treatment site.
With Alocuro Pure PRF+ protocol, typically 8-9mL of PRF for injection is gained from a 15mL blood sample.
How is Alocuro Pure PRF+ different to Alocuro PRP?
Platelet‑Rich Fibrin (PRF) delivers regenerative properties similar to Platelet‑Rich Plasma (PRP), but is produced without anticoagulant, allowing the clotting cascade to proceed ‘ex-vivo’ and form a physiologic fibrin matrix suitable for injection or surgical placement.
The 3D fibrin matrix provides a temporary structural framework for tissue regeneration and wound healing, offers subtle short‑term volume (typically up to two weeks), and supports tissue repair alongside platelet‑derived bioactive proteins.
Pure PRF+ is particularly useful in clinical contexts where a fibrin‑based scaffold or an effect of a ‘fibrin glue’ will assist a patient’s clinical situation. In treatment areas where liquid PRP may ‘leak’ from the target site, such as within a tooth socket after tooth extraction, the fibrin matrix traps platelets and leukocytes within its scaffold so they remain within the target tissue for a longer period of time.
The platelet-rich fibrin matrix also acts as a regenerative biological material that facilitates aggregation of adherent cells (e.g., stem cells) at the healing interface.
Alocuro’s ARTG-listed platelet-concentrating system enables preparation of both PRP and PRF from a single platform, giving clinics flexibility to select the most appropriate autologous product without additional specialised equipment.